替罗非班在急性冠脉综合征患者经皮冠脉介入术中的应用效果

doi:10.3969/j.issn.1671-7171.2025.02.020

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1244 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effect of Tirofiban on percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS).【Methods】A total of 100 patients with ACS who underwent PCI treatment in our hospital from March 2020 to March 2023 were selected and divided into observation group and control group according to random number table method, with 50 cases in each group. The control group was given routine treatment, the observation group was given intravenous tirofiban during PCI. TIMI blood flow grading, myocardial enzyme profile indexes [creatine kinase isoenzyme (CK-MB), troponin I(cTnI), lactate dehydrogenase (LDH)], major adverse cardiovascular events (MACE) and bleeding complications were compared between the two groups.【Results】After treatment, TIMI blood grading in both groups was significantly improved compared with that before surgery, and TIMI blood grading in the observation group was better than that in the control group, the difference was statistically significant (P<0.05). After treatment, serum CK-MB, cTnI and LDH levels in the 2 groups were lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). After 3 months of follow-up, the incidence of MACE in the observation group was significantly lower than that in the control group, with statistical significance (P<0.05). No serious bleeding occurred in all patients during treatment, and there was no significant difference in the incidence of bleeding complications between the two groups (P>0.05).【Conclusion】The use of Tirofiban during perioperative PCI can effectively improve the coronary artery flow and myocardial injury in ACS patients, reduce the incidence of MACE, and do not increase the risk of bleeding.

Key words： Acute Coronary Syndrome Tirofiban Percutaneous Coronary Intervention

Received: 31 July 2023

PACS:

R543.31

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Jinwei
	ZHOU Qian

Cite this article:

ZHANG Jinwei,ZHOU Qian. Effect of Tirofiban on Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(2): 246-248.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.02.020 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I2/246

[1] 郑轶, 尚树忠, 郭三强, 等. 急性冠脉综合征患者介入应用替罗非班对冠脉血流和心肌灌注的影响[J].医药论坛杂志, 2012, 33(5):49-50.
[2] 王锦,车奕宏.hs-CRP、NT-proBNP预测急性冠脉综合征患者PCI 术后发生心血管事件的价值[J].医学临床研究,2021,38(12):1903-1905.
[3] 高群,庞雅桢.ACS患者择期PCI术中冠脉内应用替罗非班对血小板微粒水平的影响[J].医学临床研究,2018,35(10):1991-1993.
[4] 王立中, 俞晓薇, 赵冬婧, 等. 替罗非班联用前列地尔对急诊经皮冠脉介入治疗术后心肌梗死患者心肌再灌注和心功能短期预后的影响[J].中国医药导报, 2013,10(17): 77-79.
[5] WIDIMSKY P, MOTOVSKA Z, BOLOGNESE L, et al. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel[J].Heart,2015, 101(15):1219-1224.
[6] 韩超.盐酸替罗非班联合肝素治疗急性冠脉综合征的疗效及安全性分析[J].中国实用医药, 2016, 11(6):161-162.
[7] 张力俨, 张翠丽, 富路. 急性心肌梗死经皮冠状动脉介入治疗研究进展[J].心血管病学进展, 2011, 32(1):64-66.
[8] 刘庆, 张新金, 李建美. 急诊经桡动脉冠脉介入治疗急性冠脉综合征中应用替罗非班的有效性和安全性[J].山东医药, 2012, 52(16):77.
[9] 高鹏. 急性冠脉综合征的治疗新进展[J].中国卫生产业,2015, 29(196):196-198.
[10] 徐风燕, 迟新栋, 帕尔哈提, 等. 替罗非班与低相对分子质量肝素钙在预防支架内血栓形成的对比研究[J].血栓与止血学, 2013, 19(4):156-157.
[11] 张利英. 冠状动脉内应用替罗非班在急性冠脉综合征患者急诊介入治疗中的疗效[J].实用临床医学杂志, 2014,18(11):146-148.
[12] 赵纯华.依替巴肽与替罗非班在急性ST段抬高型心肌梗死病人PCI治疗中的疗效及安全性对比研究[J].中西医结合心脑血管病杂志, 2017,15(19):2434-2437.
[13] SCHNEIDER D J. Current issues with glycoprotein Ⅱb/Ⅲa antagonists[J].Curr Drug Targets,2011, 12(12): 1813-2180.
[14] PURI A, BANSAL A, NARAIN V S, et al. Comparative assessment of platelet GpⅡb/Ⅲa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI[J].Indian Heart J,2013, 65(2):152.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(2): 296-298.